Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DH Stock Forecast 2025-2026
$2.46
Current Price
$258.13M
Market Cap
Buy 3
Hold 9
Sell 1
Wall St Analyst Ratings
Distance to DH Price Targets
+143.9%
To High Target of $6.00
+62.6%
To Median Target of $4.00
+22.0%
To Low Target of $3.00
DH Price Momentum
-13.4%
1 Week Change
-16.0%
1 Month Change
-47.2%
1 Year Change
-40.1%
Year-to-Date Change
-56.7%
From 52W High of $5.68
+14.4%
From 52W Low of $2.15
📊 TOP ANALYST CALLS
Did DH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Definitive Healthcare is one of their latest high-conviction picks.
Latest DH Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, DH has a neutral consensus with a median price target of $4.00 (ranging from $3.00 to $6.00). The overall analyst rating is N/A (N/A/10). Currently trading at $2.46, the median forecast implies a 62.6% upside. This outlook is supported by 3 Buy, 9 Hold, and 1 Sell ratings.
The most optimistic forecast comes from David Grossman at Stifel, projecting a 143.9% upside. Conversely, the most conservative target is provided by Kash Rangan at Goldman Sachs, suggesting a 22.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DH Analyst Ratings
3
Buy
9
Hold
1
Sell
DH Price Target Range
Low
$3.00
Average
$4.00
High
$6.00
Current: $2.46
Latest DH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 10, 2025 | Canaccord Genuity | David Hynes | Hold | Maintains | $4.00 |
| Aug 8, 2025 | Stifel | David Grossman | Buy | Maintains | $6.00 |
| May 12, 2025 | Goldman Sachs | Kash Rangan | Neutral | Maintains | $3.40 |
| Mar 4, 2025 | Goldman Sachs | Kash Rangan | Neutral | Maintains | $3.00 |
| Mar 3, 2025 | Barclays | Saket Kalia | Underweight | Maintains | $3.00 |
| Jan 16, 2025 | Needham | Ryan MacDonald | Hold | Reiterates | $N/A |
| Jan 13, 2025 | Barclays | Saket Kalia | Underweight | Downgrade | $4.00 |
| Dec 20, 2024 | Stephens & Co. | Equal-Weight | Initiates | $N/A | |
| Nov 8, 2024 | Needham | Ryan MacDonald | Hold | Reiterates | $N/A |
| Sep 17, 2024 | BTIG | David Larsen | Buy | Initiates | $7.00 |
| Aug 9, 2024 | Deutsche Bank | George Hill | Hold | Maintains | $5.00 |
| Aug 7, 2024 | Barclays | Saket Kalia | Equal-Weight | Maintains | $4.00 |
| Aug 7, 2024 | Baird | Vikram Kesavabhotla | Neutral | Maintains | $5.00 |
| Aug 6, 2024 | Morgan Stanley | Craig Hettenbach | Equal-Weight | Maintains | $5.00 |
| Aug 6, 2024 | Needham | Ryan MacDonald | Hold | Reiterates | $N/A |
| Jul 31, 2024 | Barclays | Saket Kalia | Equal-Weight | Maintains | $6.00 |
| Jul 31, 2024 | JP Morgan | Anne Samuel | Underweight | Downgrade | $5.00 |
| Jul 31, 2024 | Stifel | David Grossman | Buy | Maintains | $7.50 |
| Jul 31, 2024 | Needham | Ryan MacDonald | Hold | Reiterates | $N/A |
| Jul 31, 2024 | Baird | Vikram Kesavabhotla | Neutral | Maintains | $6.00 |
Definitive Healthcare Corp (DH) Competitors
The following stocks are similar to Definitive Healthcare based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
DH
Definitive Healthcare
mkt cap
258.13M
Definitive Healthcare Corp (DH) Financial Data
Definitive Healthcare Corp has a market capitalization of $258.13M with a P/E ratio of -0.7x. The company generates $242.28M in trailing twelve-month revenue with a -77.9% profit margin.
Revenue growth is -4.2% quarter-over-quarter, while maintaining an operating margin of -5.6% and return on equity of -49.2%.
Valuation Metrics
Market Cap
$258.13M
Enterprise Value
$350.49M
P/E Ratio
-0.7x
PEG Ratio
0.0x
Price/Sales
1.1x
Growth & Margins
Revenue Growth (YoY)
-4.2%
Gross Margin
+76.6%
Operating Margin
-5.6%
Net Margin
-77.9%
EPS Growth
-4.2%
Financial Health
Cash/Price Ratio
+73.2%
Current Ratio
1.6x
Debt/Equity
45.0x
ROE
-49.2%
ROA
-0.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Definitive Healthcare Corp (DH) Business Model
About Definitive Healthcare Corp
What They Do
Provides healthcare data and analytics solutions.
Business Model
The company operates a data platform that caters to various sectors within the healthcare ecosystem, including life sciences, providers, payers, and healthcare IT companies. It generates revenue by offering insights and analytics that help clients optimize operations and enhance decision-making.
Additional Information
Definitive Healthcare Corp is dedicated to fostering a transparent healthcare environment, supporting industry advancements, and helping clients identify opportunities to reduce costs. The company emphasizes innovation and accuracy, making it a valuable resource for healthcare professionals aiming to improve patient outcomes and strategic growth.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
782
CEO
Mr. Kevin D. Coop
Country
United States
IPO Year
2021
Website
www.definitivehc.comDefinitive Healthcare Corp (DH) Latest News & Analysis
Latest News
Quick Summary
Definitive Healthcare Corp. will host its Q3 2025 earnings call on November 6, 2025, at 5:00 PM EST, featuring key executives and analysts from various firms.
Why It Matters
Definitive Healthcare's Q3 earnings call provides critical insights into financial performance and future outlook, influencing investor confidence and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Definitive Healthcare Corp. (Nasdaq: DH) announced its financial results for Q3 2025, ending September 30. Further details on performance were not included in the excerpt.
Why It Matters
Definitive Healthcare's Q3 financial results can impact stock performance, investor sentiment, and market positioning within the healthcare intelligence sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Definitive Healthcare Corp. (DH) reported Q3 earnings of $0.07 per share, exceeding the Zacks estimate of $0.06, but down from $0.10 per share in the same quarter last year.
Why It Matters
Definitive Healthcare's earnings beat expectations, indicating strong performance. However, the year-over-year decline in earnings may raise concerns about future growth potential.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Definitive Healthcare Corp. (Nasdaq: DH) will report Q3 2025 financial results on November 6, 2025, after market close, and hold a conference call at 5 PM ET to discuss the results.
Why It Matters
Definitive Healthcare's upcoming earnings report and conference call may influence stock performance, providing insights into financial health and market strategy, which can impact investor decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Forum Ventures Bets Big on Category-Defining Vertical AI Solution for Healthcare Growth, Salubrum
1 month ago
Quick Summary
Salubrum launched a new AI-driven commercialization engine for healthcare, partnering with Definitive Healthcare (NASDAQ: DH) to enhance patient activation and marketing efficiency.
Why It Matters
Salubrum's AI-driven solution could disrupt healthcare marketing, enhancing efficiency and effectiveness. Its partnership with Definitive Healthcare may strengthen market position and drive growth, affecting investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Definitive Healthcare (DH) has been upgraded to a Zacks Rank #2 (Buy), indicating improved earnings outlook and potential for stock price increase.
Why It Matters
Definitive Healthcare's upgrade to a Zacks Rank #2 signals positive earnings expectations, potentially boosting investor confidence and driving the stock price upward.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About DH Stock
What is Definitive Healthcare Corp's (DH) stock forecast for 2026?
Based on our analysis of 16 Wall Street analysts, Definitive Healthcare Corp (DH) has a median price target of $4.00. The highest price target is $6.00 and the lowest is $3.00.
Is DH stock a good investment in 2026?
According to current analyst ratings, DH has 3 Buy ratings, 9 Hold ratings, and 1 Sell ratings. The stock is currently trading at $2.46. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DH stock?
Wall Street analysts predict DH stock could reach $4.00 in the next 12 months. This represents a 62.6% increase from the current price of $2.46. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Definitive Healthcare Corp's business model?
The company operates a data platform that caters to various sectors within the healthcare ecosystem, including life sciences, providers, payers, and healthcare IT companies. It generates revenue by offering insights and analytics that help clients optimize operations and enhance decision-making.
What is the highest forecasted price for DH Definitive Healthcare Corp?
The highest price target for DH is $6.00 from David Grossman at Stifel, which represents a 143.9% increase from the current price of $2.46.
What is the lowest forecasted price for DH Definitive Healthcare Corp?
The lowest price target for DH is $3.00 from Kash Rangan at Goldman Sachs, which represents a 22.0% increase from the current price of $2.46.
What is the overall DH consensus from analysts for Definitive Healthcare Corp?
The overall analyst consensus for DH is neutral. Out of 16 Wall Street analysts, 3 rate it as Buy, 9 as Hold, and 1 as Sell, with a median price target of $4.00.
How accurate are DH stock price projections?
Stock price projections, including those for Definitive Healthcare Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 3:31 PM UTC